Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

5.260 -0.060 (-1.13%)
Streaming Delayed Price Updated: 11:31 AM EDT, Aug 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 Next >
The 3 Best Gene Editing Stocks to Buy in August 2024
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases. 
Via InvestorPlace
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it. 
Via InvestorPlace
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
From Silence Therapeutics plc
Via Business Wire
The Analyst Landscape: 6 Takes On Silence Therapeutics
 
Via Benzinga
What 7 Analyst Ratings Have To Say About Silence Therapeutics
 
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
 
Via Benzinga
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024
Silence Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
From Silence Therapeutics plc
Via Business Wire
What 4 Analyst Ratings Have To Say About Silence Therapeutics
 
Via Benzinga
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
From Silence Therapeutics plc
Via Business Wire
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one. 
Via InvestorPlace
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday. 
Via Benzinga
What's Going On With Silence Therapeutics Stock Today?
Silence Therapeutics reports narrower Q4 loss, data from zerlasiran study, and strengthened cash position. In March 2024, Mallinckrodt notified Silence that they will not pursue further development of... 
Via Benzinga
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
From Silence Therapeutics plc
Via Business Wire
Earnings Scheduled For March 12, 2024
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter. 
Via Benzinga
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
From Silence Therapeutics plc
Via Business Wire
Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday. 
Via Benzinga
Topics Stocks
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Silence Therapeutics plc
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
From Silence Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.